We provide you with 20 years of free, institutional-grade data for ARDS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ARDS. Explore the full financial landscape of ARDS stock.
| Reported Date | CIK | Ticker | Type |
|---|
Aridis Pharmaceuticals, Inc(NASDAQ:ARDS) 
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (Ig...
Website: http://www.aridispharma.com
Founded: 2003
Full Time Employees: 25
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ARDS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.